1. Supplemental Figure 1 Tissue: ColorectumLungsVaginal wall Route: ICRIN IVAG IVAG (Depo) Dose: 2x10 9 5x10 8 1x10 9 0 1 2 3 4 5 6 7 8 9 Luc RLU (log10) RLU/mg tw RLU/tissue *** **

2. Supplemental Figure 2 0% 20% 40% 60% 80% 100% 01020304050 Mortality 0.0 1.0 2.0 3.0 4.0 5.0 123456789 Pathology Score 2×10 6 PFU 2×10 5 PFU 2×10 4 PFU 2×10 3 PFU 2×10 2 PFU 0.0 1.0 2.0 3.0 4.0 5.0 6.0 1234567 Total PFU/sample Days post infection Mortality Rectal virus shedding Perianal pathology

3. Supplemental Figure 3 UnprotectedProtected after AdgB ICR

4. Supplemental Figure 4 Pathology score 0 1 2 3 4 5 01234567 0 20 40 60 80 100 Mortality (%) 01020304050 CD8 -/- IFN-  -/- IL-12 -/- Days post infection Perianal pathology Mortality WT

5. Supplemental Figure 5 abab 0.0 1.0 2.0 3.0 4.0 5.0 7 Total PFU/sample *** ** *** 0 1 2 3 4 5 1234567 Pathology score *** 0% 20% 40% 60% 80% 100% 01020304050 Mortality UnimmunizedAdgB IN/INAdgB ICR/IN 0 1 2 3 4 5 1234567 Pathology score *** * 0.0 1.0 2.0 3.0 4.0 5.0 7 Total PFU/sample *** 0% 20% 40% 60% 80% 100% 01020304050 Mortality Days post infection Perianal pathology Rectal virus shedding Mortality Perineal pathology Vaginal virus shedding Mortality

6. Supplemental Figure 6 abab 0 20 40 60 80 100 01020304050 Mortality (%) Unimmunized AdgB IVAG (Depo) AdgB IVAG Pathology score 0 1 2 3 4 5 01234567 0 1 2 3 4 5 01234567 0 20 40 60 80 100 Mortality (%) 01020304050 Unimmunized AdgB IVAG (Depo) AdgB IVAG Days post infection Perianal pathology Mortality

7. Supplemental Figure 1 Local gene transfer by different mucosal routes. At two days after AdLuc administration via ICR, IN and IVAG (with or without prior Depo- Provera treatment), luciferase activities were determined by measuring luminescence in each corresponding tissue as RLU per tw (density) or whole organ tissue (total mass). At specified doses used for immune function studies, there was no statistical difference in the density or total mass of gene expression among different locations (P > 0.05) except for the vaginal tissue after IVAG without Depo-Provera and the mass after IVAG with Depo-Provera. Averaged density of gene expression in the colorectum did not exceed that in the lung or vaginal tract. The values are the mean ±s.d. of 3 mice in each group. Asterisks indicate significantly lower RLU compared to other groups. Supplemental Figure 2 Perianal inflammation (pathology) and hindlimb paralysis developed in the HSV-2 rectal challenge model. Doses of HSV-2 for rectal challenge were titrated (N=10/group except for the groups of 2x102 and 2x103, N=5). The absolute lethal dose (LD100) of HSV-2 was determined as 1x105 PFU, at and above which animals developed 100% hindlimb paralysis (left panel; 100% mortality) and the disease never resolved. Similar to vaginal HSV-2 infection (76;80), rectally infected mice having received LD doses displayed uncontrolled virus replication (middle panel; relatively constant from day 1 till death, with a tendency to increase at day 2-3), increasingly severe perianal inflammation and ulcerative lesions (right panel), and paralysis of hindlimbs developed within 7-10 days.

8. Supplemental Figure 3 Protection from HSV-2 rectal challenge in mice immunized ICR with AdgB. Left panel: at day 7 after rectal challenge of 2x105 PFU of HSV-2, unimmunized mice developed the disease, severe perianal lesion (white arrow) and paralyzed hindlimb (black arrow). Right panel: in contrast, AdgB ICR immunized mice survived with diminished pathology and the disease was completely resolved by day 7 (no lesion or paralysis developed). Supplemental Figure 4 Protection at the large intestinal mucosa against HSV-2 depends on cellular immunity. Fourteen days after AdgB ICR immunization of gene knockout mice as indicated, mice were challenged rectally with 2x105 PFU of HSV-2. Pathology score (left panel) and mortality (right panel) were measured. At least 5 mice in each group. Supplemental Figure 5 Mucosal prime/boost vaccination requires large intestine immunization to induce full protection against herpes infection. Intranasal prime/boost (IN/IN) is often used to enhance mucosal immune responses. This regimen was compared with priming/boosting of mice by ICR/IN with a 2-week interval. Two weeks after the boost, animals were challenged with HSV-2 at a dose of 2x106 PFU at colorectal mucosa (a) or 2x105 PFU at vaginal mucosa (b) (N=5/group). Parianal pathology (left panels), virus shedding (middle panels) and mortality (right panels) were compared. Asterisks in left panels and right panels indicate a statistical difference of the group in comparison with ICR/IN group.

9. Although IN/IN was statistically different from unimmunized in pathology (left panel, p<0.05) and mortality (right panel, p<0.01), ICR/IN provided more potent mucosal protection than IN/IN. *, ** and *** indicate p<0.05, 0.01 and 0.001, respectively. Supplemental Figure 6 IVAG immunization fails to protect from HSV-2 challenge. Mice were immunized IVAG with 1x109 PFU of AdgB with or without prior Depo- Provera (33) and 3 weeks later challenged with 2x105 PFU of HSV-2 at either vaginal (a) or colorectal mucosa (b). Pathology (left panels) and mortality (right panels) were examined. N=5/group. No protection was seen after IVAG immunization.